

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934  
(Amendment No. 2)\*

Glycomed Incorporated

(Name of Issuer)

Common Stock

(Title of Class of Securities)

380002 10 5  
(CUSIP Number)

Check the following box if a fee is being paid with the statement \_\_. (A fee is not required only if the reporting person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7).

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 380002 10 5

(1) Name of Reporting Person: Eli Lilly and Company  
S.S. or I.R.S. Identification No. of Above Person 35-0470950

(2) Check the Appropriate Box if a Member of a Group (a) \_\_\_  
(b) \_\_\_  
Not Applicable

(3) SEC Use Only

(4) Citizenship or Place of Organization Indiana

Number of Shares Beneficially Owned by Each Reporting Person With	(5) Sole Voting Power	722,463
	(6) Shared Voting Power	None
	(7) Sole Dispositive Power	722,463
	(8) Shared Dispositive Power	None

(9) Aggregate Amount Beneficially Owned by Each Reporting Person	722,463
(10) Check if the Aggregate Amount In Row (9) Excludes Certain Shares	Not Applicable
(11) Percent of Class Represented by Amount in Row (9)	5.73% at December 31, 1993
(12) Type of Reporting Person	CO
Item 1(a).	Name of Issuer Glycomed Incorporated
Item 1(b).	Address of Issuer's Principal Executive Offices 860 Atlantic Avenue Alameda, CA 94501
Item 2(a).	Name of Person Filing Eli Lilly and Company
Item 2(b).	Address of Principal Business Office or, if None, Residence Lilly Corporate Center Indianapolis, IN 46285
Item 2(c).	Citizenship Indiana
Item 2(d).	Title of Class of Securities Common Stock
Item 2(e).	CUSIP No. 380002 10 5
Item 3.	Status of Filer Under Rules 13d-1(b) or 13d-2(b) Not applicable
Item 4.	Ownership (a) Amount Beneficially Owned 722,463 (b) Percent of Class 5.73% as of December 31, 1993
(c) Voting and Dispositive Power	
	Sole voting power 722,463
	Shared voting power None
	Sole dispositive power 722,463
	Shared dispositive power None

Item 5.	Ownership of Five Percent or Less of a Class  Not applicable
Item 6.	Ownership of More Than Five Percent on Behalf of Another Person  Not applicable
Item 7.	Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company  Not applicable
Item 8.	Identification and Classification of Members of the Group  Not applicable
Item 9.	Notice of Dissolution of Group  Not applicable
Item 10.	Certification  Not applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ELI LILLY AND COMPANY

BY: s/James M. Cornelius  
James M. Cornelius, Vice  
President, Finance, and  
Chief Financial Officer

Date: February 14, 1994